UnicoCell Biomed CoTPE:6794 +4.67%83 Gross Margin % is 48.84% as of Dec. 2025, which is 32% below its 10-year median of 71.32. GuruFocus rates TPE:6794 with a GF Score™ of 83/100 and a GF Value™ of NT$101.57 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 729 Biotechnology companies, UnicoCell Biomed Co ranks better than 52.26% on this metric.
The historical rank and industry rank for UnicoCell Biomed Co's Gross Margin % or its related term are showing as below:
TPE:6794'
s Gross Margin % Range Over the Past 10 Years
Min: 56.93 Med: 71.32 Max: 82.68
Current: 63.04
During the past 9 years, the highestGross Margin % of UnicoCell Biomed Co was 82.68%. The lowest was 56.93%. And the median was 71.32%.
TPE:6794's Gross Margin % is ranked better than 52.26% of 729
companies
in the Biotechnology industry
Industry Median: 60.92
vs TPE:6794: 63.04
UnicoCell Biomed Co had a gross margin of 48.84% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for UnicoCell Biomed Co was 0.90% per year.
UnicoCell Biomed Co (TPE:6794) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
UnicoCell Biomed Co had a gross margin of 48.84% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
UnicoCell Biomed Co Gross Margin % Related Terms
UnicoCell Biomed Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for UnicoCell Biomed Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6794 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, UnicoCell Biomed Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UnicoCell Biomed Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where UnicoCell Biomed Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
UnicoCell Biomed Co (TPE:6794) has a Gross Margin % of 48.84% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on UnicoCell Biomed Co and its competitors. This is 32% below median its historical median of 71.32. Over the past decade, UnicoCell Biomed Co's Gross Margin % has ranged from 56.93 to 82.68. According to the industry distribution chart, UnicoCell Biomed Co ranks #348 out of 729 companies in the Biotechnology industry, placing it in the top 47.7%.
Is UnicoCell Biomed Co's Gross Margin % too high?
UnicoCell Biomed Co's current Gross Margin % of 48.84% is 32% below median its 10-year median of 71.32. Over the past 10 years, this metric has ranged from a low of 56.93 to a high of 82.68. The Biotechnology industry median Gross Margin % is 60.92. UnicoCell Biomed Co's value of 48.84% is 19.8% below this industry median. Based on the distribution chart, UnicoCell Biomed Co ranks #348 out of 729 companies in the Biotechnology industry, which is above the industry midpoint. Overall, UnicoCell Biomed Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UnicoCell Biomed Co ranks #348 out of 729 companies for Gross Margin %. This puts UnicoCell Biomed Co in the upper half of its industry. The industry median Gross Margin % is 60.92. UnicoCell Biomed Co's value of 48.84% is 19.8% below this benchmark. Historically, UnicoCell Biomed Co's own Gross Margin % has ranged from 56.93 to 82.68 over the past decade. While the company's 10-year median is 71.32 vs. the industry median of 60.92, UnicoCell Biomed Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 729 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UnicoCell Biomed Co's current Gross Margin % of 48.84% is 19.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on UnicoCell Biomed Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UnicoCell Biomed Co's current Gross Margin % is 48.84%, which is 32% below median its own 10-year median of 71.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$101.57, compared to a current price of NT$85.20 — trading 16.1% below its estimated fair value. The current Gross Margin % is 48.84%, which is 32% below median its 10-year median of 71.32 and 19.8% below the Biotechnology industry median of 60.92. UnicoCell Biomed Co's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current Gross Margin % is 48.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?
Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be undervalued.
The current stock price of NT$85.20 is trading 16.1% below its estimated GF Value™ of NT$101.57.
GuruFocus considers UnicoCell Biomed Co to be Modestly Undervalued.
Key valuation signals for TPE:6794:
Gross Margin %: 48.84% (32% below median its 10-year median of 71.32)
GF Value™: NT$101.57 vs. price of NT$85.20 (16.1% below fair value)
Industry Position: 19.8% below the Biotechnology median (#348 of 729)
No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
83GF Score
Get the complete analysis for TPE:6794
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6794 has been successfully added to your 
